COLUMBIA, S.C. – A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients had out-of-pocket costs for follow-up breast cancer diagnostic tests in 2023. These follow-up tests, including diagnostic mammograms, MRIs, ultrasounds or biopsies, are medically recommended next